<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04969445</url>
  </required_header>
  <id_info>
    <org_study_id>HPV-PRO-003-3</org_study_id>
    <nct_id>NCT04969445</nct_id>
  </id_info>
  <brief_title>The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female</brief_title>
  <official_title>The Durability of Protection Study of A Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Women Aged 18 to 45 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jun Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xiamen Innovax Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xiamen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the durability of protection of&#xD;
      Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine administered in females aged&#xD;
      18-45 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a follow-up study that is based on phase III clinical study of a recombinant human&#xD;
      papillomavirus 16/18 bivalent vaccine in females aged 18-45 years (Unique Protocol ID:&#xD;
      HPV-PRO-003, Identifiers: NCT01735006). The investigators will recruit people who have&#xD;
      participated in phase III clinical study on Hebei Province before and to evaluate the&#xD;
      durability of protection of the bivalent HPV vaccine on 90m and 114m after dose 1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">July 27, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With CIN2+ and/or VIN2+ and/or VaIN2+ Associated With HPV-16 and/or -18 Cervical Infection on 90m and 114m after dose 1</measure>
    <time_frame>expected 2-3 years</time_frame>
    <description>To observe the number of Subjects With Histopathologically-confirmed CIN2+ and/or VIN2+ and/or VaIN2+ Associated With HPV-16 and/or -18 Cervical Infection on 90m and 114m after dose 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With HPV-16 and/or -18 persistent cervical infection(6-month+ definition) on 90m and 114m after dose 1</measure>
    <time_frame>expected 2-3 years</time_frame>
    <description>To detect the HPV16 and HPV18 DNA on the gynecological specimens ( Cervical exfoliated cell specimens and biopsy specimens) collected from the subjects</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">647</enrollment>
  <condition>Cervical Intraepithelial Neoplasia</condition>
  <condition>Cervical Cancer</condition>
  <condition>Vaginal Intraepithelial Neoplasia</condition>
  <condition>Vulvar Intraepithelial Neoplasia</condition>
  <condition>Persistent Infection</condition>
  <arm_group>
    <arm_group_label>Vaccine group</arm_group_label>
    <description>Participants in this arm have received 3 doses of HPV 16/18 bivalent vaccine that contains 40μg HPV 16 virus-like particle antigen and 20μg HPV 18 virus-like particle antigen adsorbed in alum-adjuvant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Participants in this arm have received 3 doses of HEV vaccine that contains 30μg HEV virus-like particle antigen adsorbed in alum-adjuvant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)</intervention_name>
    <description>The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant</description>
    <arm_group_label>Vaccine group</arm_group_label>
    <other_name>There is no other Intervention in this study</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        In Hebei Province, participants who participated in the Phase III clinical study of a&#xD;
        recombinant human papillomavirus 16/18 bivalent vaccine in females (Unique Protocol ID:&#xD;
        HPV-PRO-003, Identifiers: NCT01735006) and received at least one dose&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants who participated in the Phase III clinical study of a recombinant human&#xD;
             papillomavirus 16/18 bivalent vaccine in females (Unique Protocol ID: HPV-PRO-003,&#xD;
             Identifiers: NCT01735006) and received at least one dose;&#xD;
&#xD;
          2. Participants can fully understand the study content and sign an informed consent form；&#xD;
&#xD;
          3. Able to comply with the requests of the study;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants used other HPV vaccine products (including both marketed and unmarketed&#xD;
             vaccines) since participating in the Phase III clinical study.&#xD;
&#xD;
          2. According to the investigator's judgment, there might be some medical, psychological,&#xD;
             social or occupational factors which might impact on the individual to obey the&#xD;
             protocol or sign the informed consent;&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>26 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ting Wu, Ph. D.</last_name>
    <role>Study Chair</role>
    <affiliation>Xiamen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chao Zhao, Doctor</last_name>
    <phone>+86-010-88324354</phone>
    <email>zhaochaocjr@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chao Zhao, Doctor</last_name>
      <phone>+86-010-88324354</phone>
      <email>zhaochaocjr@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Xiamen University</investigator_affiliation>
    <investigator_full_name>Jun Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Durability of Protection</keyword>
  <keyword>Human Papillomavirus 16</keyword>
  <keyword>Human Papillomavirus 18</keyword>
  <keyword>vaccine</keyword>
  <keyword>females</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

